Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Paraproteinemias × Rifaximin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Paraproteinemias 1 Neoplasms 1

Interventions

dacetuzumab 2 Dexamethasone 2 filanesib 1 ficlatuzumab 1 Steroids 1 Rifaximin 1 Proteasome Inhibitors 1 Lenalidomide 1 Injections, Subcutaneous 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Erlotinib Hydrochloride 1 Calcium Dobesilate 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03820817 2025-04-20

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Active not recruiting

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon ⚡